Neophore's SAB member publishes article on JCO Precision Oncology

Dr. Luis Diaz, Neophore’s Scientific Advisory Member and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Hospital has recently published the paper entitled "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High”. The study underpins Neophore’s therapeutic concept by describing how patients with loss of protein expression due to cancer obtain clinical benefit from immune checkpoint inhibitors. See full article here: bit.ly/2VveVTB